[Cell therapy for renal cell carcinoma].
Renal cell carcinoma (RCC) is an immunogenic tumor that has shown some response to cytokine-therapy and other types of immune-based treatment. Since the advent of lymphocyte culture techniques in the 1980s, clinical trials of lymphokine-activatedkiller cells and tumor infiltrating lymphocytes have been conducted. Although these approaches have not shown apparent benefit compared to the standard cytokine therapy, further trials are ongoing using dendritic cell or gene-modified tumor vaccines in order to induce a tumor-specific cytotoxic T cell response in vivo. Recently, several investigators have indicated that RCC is susceptible to a graft-versus-tumor effect promoted by allogeneic stem-cell transplantation. This article reviews the clinical results of these cell therapies for metastaic RCC.
Kawai
Koji
K
Department of Urology, Institute of Clinical Medicine, University of Tukuba, 1-1-1 Tennoudai, Tsukuba, Ibaragi 305-8575, Japan.
D019496:Cancer Vaccines / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D015316:Genetic Therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation*; D033581:Stem Cell Transplantation
D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor